- Clinical Trials
- April 2025
- 60 Pages
Global
From €1317EUR$1,500USD£1,146GBP
- Report
- April 2025
- 175 Pages
Global
From €3941EUR$4,490USD£3,429GBP
- Clinical Trials
- April 2025
- 180 Pages
Global
From €2194EUR$2,500USD£1,909GBP
- Report
- April 2025
- 200 Pages
Global
From €6978EUR$7,950USD£6,071GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1097EUR$1,250USD£955GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1097EUR$1,250USD£955GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1097EUR$1,250USD£955GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2448EUR$2,789USD£2,130GBP
- Report
- November 2025
- 150 Pages
Global
From €3379EUR$3,850USD£2,940GBP
€4257EUR$4,850USD£3,704GBP
- Report
- August 2023
- 150 Pages
United States
From €3292EUR$3,750USD£2,864GBP
- Report
- May 2023
- 196 Pages
Global
From €2194EUR$2,500USD£1,909GBP
P-Selectin is a type of hematological drug used to treat a variety of conditions related to the blood, such as thrombosis, inflammation, and cancer. It is a type of cell adhesion molecule that binds to other cells, allowing them to stick together and form clots. P-Selectin is also involved in the process of leukocyte rolling, which is important for the immune system to respond to infection.
P-Selectin is used in a variety of treatments, including anticoagulants, anti-inflammatory drugs, and cancer therapies. It is also used in research to study the role of cell adhesion molecules in the development of diseases.
The P-Selectin market is highly competitive, with many companies offering products for different applications. Some of the major players in the market include Merck, Pfizer, Novartis, Sanofi, and Bristol-Myers Squibb. Other companies include AstraZeneca, GlaxoSmithKline, and Roche. Show Less Read more